Scope Fluidics S.A. Logo

Scope Fluidics S.A.

Biotechnology firm that incubates and sells microfluidic diagnostic projects.

SCP | WAR

Overview

Corporate Details

ISIN(s):
PLSCPFL00018
LEI:
259400EUNFX4E2BEHU15
Country:
Poland
Address:
WARSZAWA OGRODOWA 58, 00-876 WARSZAWA

Description

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-09-19 08:10
Skonsolidowane sprawozdanie finansowe GK Scope Fluidics za H1 2025
Polish PDF 1.0 MB
2025-09-19 08:10
Sprawozdanie z działalności GK Scope Fluidics za H1 2025
Polish PDF 2.1 MB
2025-09-16 17:02
Aktualizacja informacji dotyczących projektu HYBOLIC - Content (PL)
Polish HTML 1.5 KB
2025-09-15 13:33
Zgoda Rady Nadzorczej na podjęcie przez Scope Fluidics działań mających na celu…
Polish HTML 5.9 KB
2025-09-09 16:50
Zmiana terminu publikacji raportu za I półrocze 2025 r. - Content (PL)
Polish HTML 522 bytes
2025-08-06 16:00
Osiągnięcie pierwszego celu oraz zatwierdzenie do realizacji drugiego celu w pr…
Polish HTML 2.4 KB
2025-07-04 13:17
Złożenie zamówienia w ramach współpracy z BIT w projekcie BACTEROMIC - Content …
Polish HTML 1.7 KB
2025-06-25 13:24
Zawarcie umowy na przeprowadzenie badań klinicznych na potrzeby certyfikacji FD…
Polish HTML 1.2 KB
2025-06-17 18:56
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na ZWZ Spółki w …
Polish PDF 82.7 KB
2025-06-17 18:56
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Wa…
Polish HTML 335 bytes
2025-06-17 18:33
Treść uchwał podjętych przez ZWZ Scope Fluidics S.A. 17.06.2025
Polish PDF 349.9 KB
2025-06-17 18:33
Treść uchwał podjętych przez ZWZ Scope Fluidics w dniu 17 czerwca 2025 r. - Con…
Polish HTML 660 bytes
2025-06-12 12:10
Nawiązanie współpracy w ramach zabezpieczenia mocy produkcyjnych - Content (PL)
Polish HTML 1.2 KB
2025-05-22 18:04
Wniosek Zarządu dotyczący podziału zysku
Polish PDF 178.9 KB
2025-05-22 18:04
Wniosek Zarządu dotyczący podziału zysku
Polish PDF 178.9 KB

Automate Your Workflow. Get a real-time feed of all Scope Fluidics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Scope Fluidics S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Scope Fluidics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.